Interchangeability between SP263 and 22C3 assays in lung cancer specimens: a reality in daily practice

被引：0
|
作者：
Jang, Min Hye [1 ]
Baek, Jina [2 ]
Shin, Kyeong-Cheol [2 ]
Lee, Jang Hoon [2 ]
机构：
[1] Yeungnam Univ Hosp, Daegu, South Korea
[2] Yeungnam Univ, Sch Med, Daegu, South Korea
来源：
MODERN PATHOLOGY | 2019年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1841
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Interchangeability between SP263 and 22C3 assays in lung cancer specimens: a reality in daily practice
    Jang, Min Hye
    Baek, Jina
    Shin, Kyeong-Cheol
    Lee, Jang Hoon
    LABORATORY INVESTIGATION, 2019, 99
  • [2] Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263
    Fujimoto, Daichi
    Yamashita, Daisuke
    Fukuoka, Junya
    Kitamura, Yuka
    Hosoya, Kazutaka
    Kawachi, Hayato
    Sato, Yuki
    Nagata, Kazuma
    Nakagawa, Atsushi
    Tachikawa, Ryo
    Date, Naoki
    Sakanoue, Ichiro
    Hamakawa, Hiroshi
    Takahashi, Yutaka
    Tomii, Keisuke
    ANTICANCER RESEARCH, 2018, 38 (12) : 6891 - 6895
  • [3] PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays
    Dabbagh, Tamara Z.
    Sughayer, Maher A.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (06) : 462 - 466
  • [4] Assay Comparability of 22C3 and SP263 Immunohistochemistry Staining in Lung Cancer; 1254 Paired Cases in Real Clinical Practice in a Single Institution
    Kim, Hyunjin
    Yoon-La, Choi
    Han, Joungho
    MODERN PATHOLOGY, 2019, 32
  • [5] Assay Comparability of 22C3 and SP263 Immunohistochemistry Staining in Lung Cancer; 1254 Paired Cases in Real Clinical Practice in a Single Institution
    Kim, Hyunjin
    Yoon-La, Choi
    Han, Joungho
    LABORATORY INVESTIGATION, 2019, 99
  • [6] Comparison of 22C3 PharmDx and SP263 Assays to Test PD-L1 Expression in NSCLC
    Sughayer, Maher A.
    Alnaimy, Farah
    Alsughayer, Anas M.
    Qamhia, Naim
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2019, 27 (09) : 663 - 666
  • [7] Concordance of Programmed Death-Ligand 1 Expression between SP142 and 22C3/SP263 Assays in Triple-Negative Breast Cancer
    Lee, Seung Eun
    Park, Ha Young
    Lim, So Dug
    Han, Hye Seung
    Yoo, Young Bum
    Kim, Wan Seop
    JOURNAL OF BREAST CANCER, 2020, 23 (03) : 303 - 313
  • [8] External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different
    Dodson, Andrew
    Parry, Suzanne
    Lissenberg-Witte, Birgit
    Haragan, Alex
    Allen, David
    O'Grady, Anthony
    McClean, Emma
    Hughes, Jamie
    Miller, Keith
    Thunnissen, Erik
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2020, 6 (02): : 138 - 145
  • [9] CT-guided transthoracic needle biopsy for evaluation of PD-L1 expression: Comparison of 22C3 and SP263 assays
    Beck, Kyongmin S.
    Kim, Seung Joon
    Kang, Jin Hyoung
    Han, Dae Hee
    Jung, Jung Im
    Lee, Kyo Young
    THORACIC CANCER, 2019, 10 (07) : 1612 - 1618
  • [10] CT-Guided Transthoracic Needle Biopsy for Evaluation of PD-L1 Expression: Comparison of 22C3 and SP263 Assays
    Beck, K.
    Lee, K. Y.
    Hong, S. J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S399 - S400
12345